Is there any data to support to use of Brentuximab in the up-front setting in the treatment of Hodgkin lymphomas?
Answer from: Radiation Oncologist at Academic Institution
Currently, Brentuximab vedotin is only approved in Hodgkin lymphoma 1) following failure of 2 multi-agent regimens or ASCT and 2) for post-ASCT maintenance. However, there are several ongoing phase II and III trials in both the US and EU examining Brentuximab vedotin in the up-front setting. The lar...
Sign in or Register to read more